Guangzhou General Pharmaceutical Research Institute

HomeArticle Show Article
Click:3088 Date:2010-5-11 11:08:39

Pharmaceutical Services

Introduce

In 1990, we established Guangzhou Pharmaceutical R & D Center of Controlled Release Dosage Forms with supporting from Guangzhou Scientific Committee and China State Pharmaceutical Administration (now called as SFDA). Since that time, we have developed near twenty extended release formulations and obtained Approval Certificates of New Drugs from the State Food and Drug Administration (SFDA). Most of them have been licensed to domestic pharmaceutical companies, and some of them to the companies in Hong Kong. The main extended release products we have developed and marketed are as follows: SR fexofenadine and pseudoephedrine Cap., CR metoprolol, CR diltiazem, SR metformin, CR salbutamol, SR naproxen, SR ibuprofen, SR theopylline, and mesalazine enteric tablets and so on. Additionally, GPRI holds many Chinese Patents for formulation technologies and products.

Main Services

Custom services and technology transter of Traditional Chinese Medicine and chemical medicine:We could provide early research, pilot scale Test and industrial research for ustained release, controlled release products. We could provide R&D service for all oral solid dosage forms, suppositories, injection products.

Redevelopment of controlled release products: We could provide services of technological improvements for the controlled release products with unstable quality, improving their quality standards and stability.

Industrial research services: We could provide the industrial research services for the approved drug, achieving the development of processes— from lab to commercialization, especially for the controlled release products.

Personalized service: We could provide professional solutions according to client demand, such as process improvement and quality standards improvement.